Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus

Reuters2025-12-23

Dec 23 (Reuters) - Nanjing Leads Biolabs <9887.HK>::
*LEADS BIOLABS AND DIANTHUS THERAPEUTICS ANNOUNCE INITIATION OF PHASE 1 TRIAL OF LBL-047 (DNTH212) IN HEALTHY VOLUNTEERS AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS $(SLE)$
*NANJING LEADS BIOLABS CO LTD: TOP-LINE RESULTS IN HEALTHY VOLUNTEERS ANTICIPATED IN 2H'26

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 23-DEC-202511:00:00.127 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593494536?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593494536","market":"us","top_or_hot":-1,"title":"Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus","media":"Reuters","content":"<html><body>Dec 23 (Reuters) - Nanjing Leads Biolabs &lt;9887.HK&gt;::<br/>*LEADS BIOLABS AND DIANTHUS THERAPEUTICS ANNOUNCE INITIATION OF PHASE 1 TRIAL OF LBL-047 (DNTH212) IN HEALTHY VOLUNTEERS AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a><br/>*NANJING LEADS BIOLABS CO LTD:  TOP-LINE RESULTS IN HEALTHY VOLUNTEERS ANTICIPATED IN 2H'26<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 23-DEC-202511:00:00.127 GMT</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-23 19:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Dec 23 (Reuters) - Nanjing Leads Biolabs &lt;9887.HK&gt;::<br/>*LEADS BIOLABS AND DIANTHUS THERAPEUTICS ANNOUNCE INITIATION OF PHASE 1 TRIAL OF LBL-047 (DNTH212) IN HEALTHY VOLUNTEERS AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a><br/>*NANJING LEADS BIOLABS CO LTD:  TOP-LINE RESULTS IN HEALTHY VOLUNTEERS ANTICIPATED IN 2H'26<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 23-DEC-202511:00:00.127 GMT</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252152.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nRSD1cYslf:1","article_id":"2593494536","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593494536","pubTimestamp":1766488480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dec 23 (Reuters) - Nanjing Leads Biolabs <9887.HK>::*LEADS BIOLABS AND DIANTHUS THERAPEUTICS ANNOUNCE INITIATION OF PHASE 1 TRIAL OF LBL-047 (DNTH212) IN HEALTHY VOLUNTEERS AND PATIENTS WITH SYSTEMIC ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","09887":"维立志博-B","DNTH":"Dianthus Therapeutics Inc.","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","BK4139":"生物科技","BK1161":"生物科技","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元"},"translate_title":"Leads Biolabs和Dianthus Therapeutics宣布在健康志愿者和系统性红斑狼疮患者中启动LBL-047（Dnth212）的1期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNTH":0.9,"09887":0.9},"content_text":"Dec 23 (Reuters) - Nanjing Leads Biolabs <9887.HK>::*LEADS BIOLABS AND DIANTHUS THERAPEUTICS ANNOUNCE INITIATION OF PHASE 1 TRIAL OF LBL-047 (DNTH212) IN HEALTHY VOLUNTEERS AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS $(SLE)$*NANJING LEADS BIOLABS CO LTD:  TOP-LINE RESULTS IN HEALTHY VOLUNTEERS ANTICIPATED IN 2H'26  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 23-DEC-202511:00:00.127 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593494536","isCrawlerRequest":true}